Search Results

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced the termination of its July 1, 2020 Strategic Research and Development Agreement with StemCell Systems GmbH (SCS) and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs.

RenovaCare, Inc., a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, announced reductions in its management team to further streamline administrative expenses.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that it is initiating a clinical trial at four burn centers in the United States.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com ), developer of patented technologies for spraying self-donated stem cells for the regeneration of organs and tissues, announced today that its Chairman, Chief Executive Officer, and President, Mr. Alan Rubino, has decided to retire. “I am proud of all that has been accomplished at RenovaCare with our management team during my leadership tenure,” stated Mr. Rubino. “I wish the Company and

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the award of a new SkinGun™ patent by the United States Patent and Trademark Office (US Patent No. 11,135,380).

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its Investigational Device Exemption (IDE) application has been granted full approval by the U.S. Food and Drug Administration (FDA). This approval enables RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds using skin cells obtained directly from the burn patient.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for the regeneration of skin and other organs and tissues, today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright BioConnect Conference, scheduled for January 11 – 14.

www.renovacareinc.com ), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company will present at the tenth annual BioPartnering Conference, hosted by BioNJ and co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, scheduled for October 6 – 7, 2020. About RenovaCare RenovaCare, Inc. is de